Press releases

Share this press release :  facebook  twitter  linkedin  google+
Publication of the second issue of Quantum Genomics' shareholder newsletter - November, 2016   (16/11/2016 17:00)

Quantum Genomics (Alternext - FR0011648971 - ALQGC), a biopharmaceutical company with the mission of developing new therapies for unsatisfied medical needs in the field of cardiovascular diseases, today announces the publication of its second shareholder newsletter.

Contents of this second issue:

  • A word from Lionel Ségard, Chairman and Chief Executive Officer of Quantum Genomics : “Since June, we have announced major progress in our various research programmes for cardiovascular diseases.”
  • Recent news : Initiation of a joint laboratory with INSERM
  • Zoom : Proceedings of the Phase IIa clinical trial in hypertension
  • Portrait : Dr. Catherine Llorens-Cortes
  • Shareholder guide

The shareholder newsletter is available on the company's website at www.quantum-genomics.com, in the Shareholder letters section of the Investors tab.

Click here to download PDF

CONTACTS
Quantum Genomics

Lionel Ségard
Chairman & Chief Executive Officer
+33 1 85 34 77 77
 
Quantum Genomics
Marc Karako
CFO – Investor Relations
+33 1 85 34 77 75
marc.karako@quantum-genomics.com
 
ACTUS finance & communication (Europe)
Jean-Michel Marmillon
Press Relations
+33 1 53 67 36 73 / jmmarmillon@actus.fr
 
The Ruth Group (U.S.)
Lee Roth / Kirsten Thomas
Investor / Public Relations
+1 646-536-7012 / +1 508-280-6592

 

ABOUT QUANTUM GENOMICS
Quantum Genomics is a biopharmaceutical company with the mission of developing new therapies for unmet medical needs in the field of cardiovascular diseases, especially hypertension and heart failure.
The Company is developing a new therapeutic approach based on BAPAI (Brain Aminopeptidase A Inhibition). This is the result of more than 20 years of academic research in the laboratories of the Collège de France, INSERM, CNRS and the University of Paris Descartes.
Quantum Genomics is listed on the Alternext market in Paris (ISIN code FR0011648971, Ticker ALQGC).
The Company has offices in Paris, France, and New York, NY, USA. For more information, please visit www.quantum-genomics.com.


Powered by Actusnews Wire (press release services) ©